Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan
Masashi Fujita(Fukushima Medical University), Hiromasa Ohira(Fukushima Medical University), Wataru Sato(Akita University), Kazumichi Abe(Fukushima Medical University), Katsunori Iijima(Akita University), Kazuo Okumoto(Yamagata University), Atsushi Masamune(Tohoku University), Masashi Ninomiya(Tohoku University), Shinsaku Fukuda, Tomohiro Katsumi(Mayo Clinic), Yoshiyuki Ueno(Yamagata Prefectural University of Health Sciences), Hidekatsu Kuroda(Iwate Medical University), Tetsu Endo(Hirosaki University), Takayoshi Oikawa(Iwate Medical University), Hiroshi Numao(Aomori Prefectural Central Hospital), Yasuhiro Takikawa(Iwate Medical University), Nobukazu Tanabe(Sendai Medical Center)
Cited by 17
Related Papers
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
|Journal of Gastroenterology|2021|424
Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis
|Cancer Research|2019|328
Variants in CPA1 are strongly associated with early onset chronic pancreatitis
|Nature Genetics|2013|305
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272